A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival
Jacqueline S. Garcia, Ronan T. Swords, Gail J. Roboz, Meagan A. Jacoby, Guillermo Garcia-Manero, Wan Jen Hong, Xiaoqing Yang, Ying Zhou, Uwe Platzbecker, David P. Steensma, Johannes E. Wolff, Pierre Fenaux
Dive into the research topics of 'A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival'. Together they form a unique fingerprint.